Cagrilintide 5mg
Cagrilintide is a long-acting amylin analog developed by Novo Nordisk. It acts on amylin receptors in the brain to reduce appetite and food intake independently of GLP-1 pathways. Phase 2 clinical trials demonstrate dose-dependent weight loss of up to 10.8% at 26 weeks. It is being developed both as monotherapy and in combination with semaglutide.
Sequence
Long-acting acylated amylin analog (37 amino acids)
Market avg: $59.99 — save 42%
Volume pricing
Pay with USDC via Coinbase Commerce
Certificate of Analysis
Independently verified by Janoshik Analytical
Test ID
JAN-CAGRI-2026-001
Purity
98.7%
Method
HPLC-MS
Batch
CAGRI-2026-01A
Test Date
February 1, 2026
Identity
Confirmed
Storage Requirements
Lyophilized
2-8°C, protect from light
Reconstituted
2-8°C, use within 14 days
Amylin receptor agonist. Refrigerate at all times.
Published Research
1 peer-reviewed studies
Once-weekly cagrilintide for weight management in people with overweight and obesity
Enebo LB, Berthelsen KK, Kankam M, et al. — New England Journal of Medicine, 2021
Phase 2 trial demonstrating cagrilintide dose-dependent weight loss.
Related Products
Research use only. All products are sold strictly for in-vitro research purposes only. Not for human consumption. Information provided references published research literature. No medical claims are made or implied.